Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
Cappuzzo F, Morabito A, Normanno N, Bidoli P, Del Conte A, Giannetta L, Montanino A, Mazzoni F, Buosi R, Burgio MA, Cerea G, Chiari R, Cortinovis D, Finocchiaro G, Foltran L, Migliorino MR, Tiseo M, Ferrari S, De Marinis F. Cappuzzo F, et al. Among authors: foltran l. Lung Cancer. 2016 Sep;99:31-7. doi: 10.1016/j.lungcan.2016.06.008. Epub 2016 Jun 14. Lung Cancer. 2016. PMID: 27565910 Clinical Trial.
Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
Saracchini S, Foltran L, Tuccia F, Bassini A, Sulfaro S, Micheli E, Del Conte A, Bertola M, Gion M, Lorenzon M, Tumolo S. Saracchini S, et al. Among authors: foltran l. Breast. 2013 Dec;22(6):1101-7. doi: 10.1016/j.breast.2013.09.001. Epub 2013 Sep 26. Breast. 2013. PMID: 24074879 Free article. Clinical Trial.
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib.
Esposito Abate R, Pasquale R, Sacco A, Piccirillo MC, Morabito A, Bidoli P, Finocchiaro G, Chiari R, Foltran L, Buosi R, Tiseo M, Giannetta L, Battiloro C, Fasola G, Romano G, Ciuffreda L, Frassoldati A, de Marinis F, Cappuzzo F, Normanno N. Esposito Abate R, et al. Among authors: foltran l. Cancers (Basel). 2019 Sep 25;11(10):1431. doi: 10.3390/cancers11101431. Cancers (Basel). 2019. PMID: 31557965 Free PMC article.
Pharmacogenetics of the systemic treatment in advanced hepatocellular carcinoma.
De Mattia E, Cecchin E, Guardascione M, Foltran L, Di Raimo T, Angelini F, D'Andrea M, Toffoli G. De Mattia E, et al. Among authors: foltran l. World J Gastroenterol. 2019 Aug 7;25(29):3870-3896. doi: 10.3748/wjg.v25.i29.3870. World J Gastroenterol. 2019. PMID: 31413525 Free PMC article. Review.
Unplanned presentations of cancer outpatients: a retrospective cohort study.
Aprile G, Pisa FE, Follador A, Foltran L, De Pauli F, Mazzer M, Lutrino S, Sacco CS, Mansutti M, Fasola G. Aprile G, et al. Among authors: foltran l. Support Care Cancer. 2013 Feb;21(2):397-404. doi: 10.1007/s00520-012-1524-6. Epub 2012 Jun 22. Support Care Cancer. 2013. PMID: 22722887
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Menghi M, Magnani M. Ruzzo A, et al. Among authors: foltran l. Br J Cancer. 2017 Oct 24;117(9):1269-1277. doi: 10.1038/bjc.2017.289. Epub 2017 Aug 24. Br J Cancer. 2017. PMID: 29065426 Free PMC article. Clinical Trial.
37 results